# CJC-1295 Ipamorelin: What the GHRH-Plus-GHRP Record Establishes > CJC-1295 Ipamorelin pairs a long-acting GHRH analogue with a selective ghrelin-receptor secretagogue. A broadsheet digest of the published literature, sourced and cited. A broadsheet reading of the published record — what the two arms each established alone, the synergy that justifies pairing them, and the line where the evidence stops. ## The short version CJC-1295 Ipamorelin is a research combination of two lab-made peptides (short protein-like molecules) used to push the body's own growth-hormone system. The first peptide, CJC-1295, is a long-acting copy of a natural signal called GHRH (the hormone that tells the pituitary gland to release growth hormone). The second, ipamorelin, is a "GHRP" — it hits a separate switch, the ghrelin receptor, to fire off a growth-hormone pulse. Pressed together, the two switches add up to a bigger pulse than either alone. Studies of the single ingredients show real, measured rises in growth hormone and IGF-1. But the fixed blend itself has never been put through a controlled human trial, and neither piece is approved as a medicine. What people report — including the downsides, from puffiness to head-rushes — is on [the effects page](/effects). ## What the CJC-1295 Ipamorelin record actually establishes The combination rests on two independent, well-attributed bodies of work. A single subcutaneous dose of CJC-1295 with DAC raised mean plasma growth hormone (GH) two- to ten-fold for six days or more and IGF-1 (insulin-like growth factor 1, the liver-made messenger that carries out most of GH's effects) 1.5- to three-fold for nine to eleven days in healthy adults; after repeat dosing, IGF-1 stayed above baseline as long as 28 days [1]. Ipamorelin, for its part, is the first *selective* GH secretagogue: unlike older peptides it released GH without dragging up the stress hormones ACTH or cortisol, even at doses more than 200 times the amount needed for half-maximal GH release [2]. The rationale for pairing them is older than either molecule. In normal men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically — the two acting through independent mechanisms [3]. That is the load-bearing finding under every "stack" claim: a [growth hormone secretagogue](/growth-hormone-secretagogue) and a GHRH analogue together produce more than the sum of their parts. ## Cjc ipamorelin: two arms, two timescales Read honestly, this is not one drug but two, and they run on different clocks. CJC-1295 with DAC carries a Drug Affinity Complex — a chemical hook that covalently bonds to Cys34 of serum albumin, the most abundant protein in blood — which stretches its action to several days [4]. Ipamorelin produces a single short pulse and clears within hours [2]. The "no-DAC" form of CJC-1295, known as Mod GRF (1-29), drops the albumin hook entirely and lasts only about thirty minutes. A reader who treats "the blend" as a single tidy thing is already off the literature: the two halves were studied apart, on timescales that do not match. The receptor-level mechanism is documented. Co-activating the cloned GHRH and ghrelin receptors in cultured cells produced a cAMP response roughly twice that of GHRH-receptor activation alone, pointing to direct cross-talk between the two pathways [5]. Synergy is real where it has been measured — in cells and in acute human GHRH-plus-GHRP studies — but it has never been measured for this specific fixed pairing. ## What the research does not show No peer-reviewed human pharmacology study has ever tested the pre-mixed CJC-1295 Ipamorelin combination itself. Every combination and efficacy claim is an inference — built from each compound's separate data plus general GHRH+GHRP synergy work that used *related* peptides, not this exact pair. Neither CJC-1295 nor ipamorelin is approved by the FDA for any human indication; both are sold only as research chemicals. Both are prohibited at all times for athletes under WADA Section S2 (peptide hormones and growth-factor mimetics). The honest framing is that the stack *raises* GH and IGF-1, with downstream effects on body composition, recovery, and sleep that are studied for the single components or extrapolated from the class — never demonstrated as established human outcomes for the blend. The mechanism is sound; the blend trial does not exist. ## How this digest is organized This site is a published register of the CJC-1295 Ipamorelin literature, kept to the line between *studied* and *extrapolated*. The [CJC-1295 Ipamorelin research](/research) desk walks the mechanism and the key trials; the [CJC-1295 Ipamorelin effects](/effects) page gathers what the research-use community reports alongside cited safety cautions; the dosage desk lays out the doses studied by species and route, with no human protocol; and the [CJC-1295 Ipamorelin references](/references) page carries every DOI and PubMed identifier behind the claims above. Two dedicated reads go deeper on the [cjc 1295 ipamorelin benefits](/benefits) reported in research and on the compound as a [growth hormone secretagogue](/growth-hormone-secretagogue). --- A front-page reading of the CJC-1295 and ipamorelin literature — a register of what the studies established, not a clinic, a vendor, or a prescription.